Linno Pharmaceuticals, Inc.
Clinical trials sponsored by Linno Pharmaceuticals, Inc., explained in plain language.
-
New drug SLN12140 aims to control kidney disease in IgA nephropathy patients
Disease control Not yet recruitingThis Phase 2 trial tests SLN12140, an experimental drug, in 48 adults with IgA nephropathy whose disease is not well-controlled by standard treatments. Participants receive different doses of SLN12140 or a placebo for 36 weeks, then all can receive the drug for another year. The …
Phase: PHASE2 • Sponsor: Linno Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New drug SLN12140 aims to control PNH in early trial
Disease control Not yet recruitingThis phase II trial tests the drug SLN12140 in 10 adults with PNH who have never taken complement inhibitors. The goal is to see if SLN12140 can reduce red blood cell destruction (measured by LDH levels) and improve hemoglobin. Participants receive different doses over 12 to 64 w…
Phase: PHASE2 • Sponsor: Linno Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC